PT - JOURNAL ARTICLE AU - Rousssos, Sotirios AU - Angelopoulos, Theodoros AU - Cholongitas, Evangelos AU - Savvanis, Spyridon AU - Papadopoulos, Nikolaos AU - Kapatais, Andreas AU - Hounta, Athina AU - Ioannidou, Panagiota AU - Deutsch, Melani AU - Manolakopoulos, Spilios AU - Sevastianos, Vasileios AU - Papageorgiou, Maria-Vasiliki AU - Vlachogiannakos, Ioannis AU - Mela, Maria AU - Elefsiniotis, Ioannis AU - Vrakas, Spyridon AU - Karagiannakis, Dimitrios AU - Pliarchopoulou, Fani AU - Chaikalis, Savvas AU - Tsirogianni, Effrosyni AU - Psichogiou, Mina AU - Kalamitsis, Georgios AU - Leobilla, Foteini AU - Paraskevis, Dimitrios AU - Malliori, Meni AU - Goulis, Ioannis AU - Papatheodoridis, Georgios AU - Hatzakis, Angelos AU - Sypsa, Vana TI - High levels of all-cause mortality among people who inject drugs in Greece in 2018–2022 AID - 10.1101/2022.10.07.22280788 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.07.22280788 4099 - http://medrxiv.org/content/early/2022/10/10/2022.10.07.22280788.short 4100 - http://medrxiv.org/content/early/2022/10/10/2022.10.07.22280788.full AB - Aims To estimate all-cause mortality in a cohort of people who inject drugs (PWID) over the period 2018–2022 in the two major cities of Greece (Athens and Thessaloniki).Methods PWID were recruited from two community-based seek-test-treat programs for HCV and HIV infections in Athens and Thessaloniki. Participants provided information on sociodemographic characteristics, injection practices, social security number, access to harm reduction and treatment. Data on the vital status and date of death were identified from the national HCV treatment registry. All-cause mortality rates (CMR) were estimated as well as age-, gender- and calendar-year standardized mortality ratios (SMR). Determinants of mortality were assessed using a Cox proportional-hazards model.Results Of 2,433 PWID, 243 (10.0%) died over a total of 6,649 person-years (PYs) of follow-up. The CMR [95% confidence interval (CI)] was 3.50 (3.08–3.97) deaths per 100 PYs; 3.03 (2.58–3.57) in Athens and 4.56 (3.74–5.57) in Thessaloniki. An increasing trend in CMR was identified over the period 2018–2022 in Athens (p for trend=0.004). The overall SMR (95% CI) was 17.17 (15.14–19.47) per 100 PYs in the combined cohort; 15.10 (12.85–17.75) in Athens and 21.72 (17.78–26.53) in Thessaloniki. The SMR was particularly increased in younger ages, females, those injecting daily, and HIV-infected PWID. Older age, living in Thessaloniki, Greek origin, homelessness, daily injecting drug use, HIV, and HCV infections were independently associated with all-cause mortality.Conclusion All-cause mortality among PWID in Greece during 2018–2022 is high with the population in Thessaloniki being particularly affected. The increasing trend in mortality in Athens might be the long-term impact of the pandemic on the health of PWID. Preventive programs such as take-home naloxone distribution and community involvement to increase harm reduction, screening, and uptake of antiretroviral and chronic hepatitis C treatment are urgently needed.Competing Interest StatementNP has served as a lecturer for Gilead and AbbVie. SM has served as lecturer/advisor/researcher for Gilead Sciences, Integris, AbbVie, Roche, Ipsen IV has served as lecturer/advisor for Gilead Sciences, Integris Pharma, Ipsen ΙΕ has served as advisor/lecturer for Gilead Sciences, Ipsen, Roche and has received unrestricted research grants from Ipsen. MP has research grant from Gilead Sciences and advisory fees from Gilead, GSK and MSD GK has received grants from Gilead. DP has received research or travel grants from Gilead Sciences, Glaxo Welcome, and Merck. ΙG has served as advisor/lecturer for Gilead Sciences, Ipsen, Roche, Integris Pharma and has received unrestricted research grants from Ipsen. GP has served as advisor/lecturer for Albireo, Amgen, Genesis, Gilead Sciences, GlaxoSmithKline, Ipsen, Janssen, Novo Nordisk, Roche, Takeda and has received research grants from Gilead Sciences. AHatzakis has received unrestricted grants from AbbVie, Gilead, and MSD. He is Co-Chair of the Hepatitis B & C Public Policy Association funded by AbbVie, Gilead, and MSD. VSypsa has received grants from Gilead and AbbVie. She has served as a lecturer for Gilead and AbbVie. SR, TA, EC, SS, AK, AHounta, PI, MD, VSevastianos, MVP, SV, DK, FP, SC, ET, FL, MMalliori and MMela have nothing to declare.Funding StatementThis study was funded by: a) The Partnership for Healthy Cities, a global network of 70 cities committed to preventing noncommunicable diseases and injuries that is supported by Bloomberg Philanthropies in partnership with the World Health Organization and the global health organization Vital Strategies. b) Gilead Sciences Hellas ARISTOTLE HCV-HIV program was supported by Gilead Sciences. ALEXANDROS program was funded by the Conquering Hepatitis via Micro-Elimination (CHIME) grant, Gilead Sciences. Additional support was provided by the Organization Against Drugs (OKANA), the Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases, AbbVie, and MSD.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ARISTOTLE HCV-HIV program was approved by the Institutional Review Board of Athens University Medical School and of the Hellenic Scientific Society for the Study of AIDS, STDs, and Emerging Diseases. ALEXANDROS program was approved by the Institutional Review Board of Athens University Medical School and of the Hellenic Scientific Society for the Study of AIDS, STDs, and Emerging Diseases. Persons who were eligible to participate based on the eligibility screening process were asked to provide written informed consent. The informed consent form included information about the program, explained that confidentiality would be protected and that participants were free to withdraw their consent at any point of the process. The questionnaire and the blood sample were linked through the RDS coupon number. The name of the participant was not recorded in the questionnaire database or on the blood collection tube. The correspondence of the name and coupon number was recorded in a separate file that could only be accessed by authorized members of the research team.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not available for sharing.